8. Restructuring

We reduced headcount in the third quarter of 2012, resulting in a restructuring accrual of $1.9 million which is being paid through August 2013. We also reduced headcount at Molecular and Progenics in the first quarter of 2013, resulting in an approximately $1.5 million restructuring charge which is being paid through the end of 2013. During the second quarter of 2013, we incurred other exit and contract termination costs, including those related to termination of the lease for Molecular's Cambridge, Massachusetts facility ($900) and amendment of the Company's Tarrytown, New York lease and consolidation within reduced facility space ($459).

Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets and research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.

	Severance and Related Benefits			Other Exit Costs			Contract Termination Costs			Total Restructuring Accrual
Balance at December 31, 2012	$	813		$	-		$	-		$	813
Additions, net		1,477			-			-			1,477
Payments		(854	)		-			-			(854	)
Balance at March 31, 2013		1,436			-			-			1,436
Additions, net		15			15			1,359			1,389
Payments		(914	)		(15	)		(1,359	)		(2,288	)
Balance at June 30, 2013	$	537		$	-		$	-		$	537